ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
July 29, 2021I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa (also known as ... -
Mortality Risk in Oropharynx Cancer Varies Based on HPV Status
January 20, 2020For patients with oropharynx cancer, the rates of head and neck cancer (HNC) mortality and competing mortality vary depending on human papillomavirus (HPV) status, with increased risks for HNC mortality and competing mortality in HPV-negative patients ...
Pharma Sources Insight January 2025
